McGhan expands breast implant trial:
This article was originally published in Clinica
Executive Summary
McGhan Medical has received permission from the US FDA to upgrade to a full-scale pivotal study the feasibility trial of its Style 410 silicone-filled breast implant. The expanded study will involve 940 patients at 100 institutions undergoing augmentation, reconstruction or revision of existing implants. McGhan, a subsidiary of Santa Barbara, California-based Inamed, says that data from the trial will form the basis of a PMA application to the FDA.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.